The cellular alterations produced in cisplatin-resistant A2780 ovarian cancer cells (A2780/R) upon treatment with the cytotoxic organogold(III) complex Aubipy c were investigated in depth through a classical proteomic approach. We observed that A2780/R cell exposure to a cytotoxic concentration of Aubipy c for 24 hours results in a conspicuous number of alterations at the protein level that were carefully examined. Notably, we observed that several affected proteins belong to the glucose metabolism system further supporting the idea that the cytotoxic effects of Aubipy c in A2780/R cells are mostly mediated by an impairment of glucose metabolism in excellent agreement with previous observations on the parent cisplatin-sensitive cell line.
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipy c in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication † ‡ 
Introduction
Ovarian cancer is the leading cause of gynecological cancers.
The most common form is epithelial ovarian cancer that is characterized by few nonspecific early symptoms and by a typical presentation only at an advanced stage, thus, explaining the poor survival statistics. 1, 2 Platinum compounds, given as a combination of cisplatin and carboplatin, are the most active chemotherapeutic agents for this disease and represent the standard treatment for nearly all women diagnosed with ovarian cancer. Although most patients initially respond to this treatment, few are cured. 3, 4 Resistance to chemotherapy is the major cause of treatment failure; resistance to cisplatin occurs in roughly one-third of women during primary treatment. Platinum-resistant disease is usually treated with non-platinum based chemotherapy regimens with a modest effect on outcome. 3, 4 Several mechanisms have been implicated in causing chemoresistance to cisplatin, such as an increased repair of cisplatin-DNA adducts; changes in the expression of cytochrome P450 genes; and alterations in the relevant apoptosis and survival pathways. Despite multiple pathways associated with drug resistance having been pinpointed by many previous studies, the underlying complex mechanisms of cisplatin resistance are far from being fully understood. 5 Because of widespread cisplatin resistance, there is an increasing interest in the development of non-cisplatin-type metal complexes as anticancer drug candidates for ovarian cancer. In recent years, organometallic compounds with a coordinated gold atom in the oxidation states +1 and +3 were focussed by several studies demonstrating a strong cytotoxicity in several cancer cell lines. [6] [7] [8] So far, the most important classes of cytotoxic gold compounds under study as prospective anticancer drug candidates have been gold(III) porphyrins, 9, 10 gold(III) dithiocarbamates, 11, 12 cyclometalated gold(III) complexes, 13 dinucleargold(III) complexes, 14, 15 goldcarbenes 16, 17 and 2,3,4,6-tetra-o-acetyl-L-thio-b-D-glucopyranosato-S-(triethyl-phosphine) gold(I) (manufactured as auranofin). 18 Gold(III) complexes display the same electronic configuration (d 8 ) and somewhat similar structural and reactivity features to proteins were involved in glucose metabolism, stress response and cell redox homeostasis. Remarkably, the bioinformatics and functional analysis of the proteomic data pointed out quite clearly that Aubipy c treatment lead to down-regulation of the glycolytic pathway. To further confirm these mechanistic results, in the present study, we performed a parallel proteomic analysis on the cellular effects of Aubipy c on cisplatin-resistant A2780 cancer cells (A2780/R). It emerged that gold treatment induced proteomic modifications similar to that achieved in A2780/S cells. Indeed, Aubipy c mainly acted by affecting the glycolytic pathway. This work therefore strengthens the role of glycolysis in the Aubipy c cytotoxic mechanism of action.
Results

Cytotoxic effects of Aubipy c
The antiproliferative properties of Aubipy c were measured in the A2780/R (cisplatin-resistant) cell line, and compared with that of cisplatin, as reported in the Experimental section. The IC 50 values, observed after exposure to both Aubipy c and cisplatin, are reported in Table 1 . After 24 h of exposure to Aubipy c , the IC 50 value was 28.87 mM whereas that of cisplatin was higher (i.e. 4100 mM). A substantial cytotoxic activity was observed after 72 h of exposure to Aubipy c . The IC 50 value of Aubipy c (9.90 mM) was lower than IC 50 of cisplatin (i.e. 24.89 mM). These data were in line with the antiproliferative properties emerged in the oncotest where Aubipy c turned out to be one of the most active gold(III) complexes in the A2780 line and it was found to be able to overcome resistance to cisplatin. 32 
Proteomic analysis
To characterize in detail the cytotoxic mechanisms of Aubipy c , the protein modifications induced by gold treatment in cisplatin-resistant A2780 ovarian cancer cell line (A2780/R) were analysed by a two-dimensional electrophoresis (2-DE) approach. A2780/R cells were treated for 24 h with Aubipy c at a concentration of 10 mM corresponding to its 72 h-exposure to IC 50 in order to reduce the cell death. Indeed, a time course of 24, 48 and 72 h of drug exposures with 10 mM of Aubipy c , by using trypan blue vital dye exclusion assay, was performed. After 24 h of exposure, the percentage of cell growth inhibition was 6.7% and the viability of the adherent cells was 95.7%. As expected, cell growth inhibition further increased at 48 h and 72 h of drug exposure reaching 37.2 and 50.7%, respectively, and the viability of the adherent cells decreased to 90.2 and 87.3%, respectively (Table S1 , ESI ‡). After Aubipy c treatment (10 mM, for 24 h), cellular protein extracts were prepared and separated by 2-D gel electrophoresis as reported in the Experimental section, and the resulting 2-DE gels were stained using a modified Neuhoff's colloidal Coomassie Blue G-250 stain (''blue silver''). 33 To obtain statistically significant results, we performed three independent experiments for both Aubipy c -treated and -untreated cells. Moreover, in order to minimize gel-to-gel variation, 2-DE was performed twice for each biological replicate and, six gels were indeed analysed for both Aubipy c -treated and control cells. In Fig. 2 , representative 2-DE gels of control ( Fig. 2A) and Aubipy c -treated 34 Moreover, we evaluated the reliability of our statistical analysis (power analysis). 35 In our experiments, we achieved a target value of 87% confirming that the number of sample replicates used was appropriate. Therefore, we considered as statistically differentially abundant the protein spots with a corrected p-value (FDR) r0.05 and a power level Z0.8. Then, we found 57 statistically differentially abundant protein spots. Among them, 35 were more abundant whereas 22 were less abundant in Aubipy c -treated cells with respect to control cells. Such protein spots are highlighted with circles and numbers in the representative gels shown in Fig. 2 . These spots were successfully identified by MALDI TOF mass spectrometry. Obtained results are shown in Table 2 , where Mascot search results, i.e. score, number of matched peptides and sequence coverage, are listed. It is noteworthy that more than one protein spot was found to correspond to the same protein, consistently with the presence of different post-translationally modified forms of the same protein ( 36, 37 In some instances, the same protein was identified in spots that displayed a strong discrepancy between the observed position on 2-DE gels and the normal M r , with a shift toward lower mass (e.g. spots 11, 21, 35, 50) , suggesting the presence of protein fragments (Table 2 and Fig. 2 ). Moreover, two differentially abundant protein spots (1 and 11) were found to be coded by the same gene HSPA4L. In particular, in Aubipy c -treated cells, we observed the decrease of the full-length protein amount (spot 1) with a concomitant increase of protein spots with lower M r (spot 11), suggesting the presence of protein degradation. Thus, the number of unique identified proteins was 48. All the identified proteins were clustered into functional categories based on the Gene Ontology (GO) terms related to their main biological functions as reported in UniprotKB database (http://www.uniprot.org/). Proteins were clustered in 10 classes and, in Fig. 3 , we reported the percentage of identified proteins annotated in each functional category. Most of the proteins were related to the category of metabolism (35.1%), protein synthesis (19.3%) and stress response and chaperones (14%). The remaining identified proteins are shared among cell cycle and apoptosis (7%), signal transduction (7%), cytoskeleton and cell structure (5.3%), transport (5.3%), cell redox homeostasis (3.5%), DNA replication and repair (1.75%), and unknown (1.75%).
Functional GO terms and pathway enrichment analysis
To gain an overall picture of the cellular changes determined by Aubipy c treatment, we sought to see whether any GO biological category was statistically over-represented among the differentially abundant proteins we identified. To this aim, we uploaded the list of the identified proteins in the web-accessible program DAVID (Database Annotation Visualization and Integrated Discovery version 6.7; http://david.abcc.ncifcrf.gov/home.jsp). Whole-cellular proteins (700 mg) were separated by 2-DE using IPG strips with a pH gradient of 3-10 nonlinear and 9-16% linear gradient SDS-PAGE. Protein spots were visualised by colloidal Coomassie blue silver staining. Black circles and numbers indicate statistically differentially abundant protein spots. Numbers correspond to the spot numbers present in Table 2 .
This journal is © The Royal Society of Chemistry 2015 The False Discovery Rate (FDR) was calculated, using Excel 2013, in order to establish how many of the significant ANOVA p-values were false positives. Only the protein spots with an adjusted p-value (FDR) o 0.05 were considered for the mass spectrometry analysis.
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Mol. BioSyst., 2015, 11, 1653--1667 | 1659 A Fisher's enrichment statistical analysis was carried out by comparing the frequencies of the annotation terms in each protein subset with that of the whole list. Fig. 4 displays the obtained GO biological process (BP) terms statistically overrepresented ( p-value r 0.1 after Benjamini correction). A detailed composition and statistical parameters were reported in Table S2 (ESI ‡). Most of the top score biological processes, enriched by the 57 identified proteins, included ontologies involved in metabolism and energy production such as the 'cellular metabolic process' (GO:0044237), the 'primary metabolic process' (GO:0044238), the 'metabolic process' (GO:0008152) and 'glycolysis' (GO:0006096). Several glycolytic enzymes such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), alpha enolase (ENO1), and fructose-bisphosphatealdolase C (ALDOC) were included in these categories. We also found mitochondrial proteins involved in energy production such as ATP synthase subunit beta and dihydrolipoyl dehydrogenase DLD (Table S2 , ESI ‡). In parallel to this GO BP enrichment analysis, we searched for statistically enriched pathways through DAVID software. We found the 'glycolysis' term with the KEGG pathway (p-value o 0.05 after Benjamini correction) and the 'metabolism of carbohydrates' term with the Reactome pathway (p-value o 0.05 after Benjamini correction) were over-represented. The proteins associated with the term 'glycolysis' are ALDOC, GAPDH, ENO1, LDHB and DLD (Table 3) .
Protein validation by 2-D western blot
Two dimensional electrophoresis followed by western blot analysis was used to validate some of the changes in protein abundance of the glycolytic enzymes revealed by 2-DE/MS analysis. The validation was performed for GAPDH and ENO1 in A2780/R cells treated for 24 h with 10 mM Aubipy c . Representative 2-D immunoblots were shown in Fig. 5A . For each tested protein, the optical density of the specific immunoreactive spot was detected and their values were statistically analysed by a two-tailed non-paired Student's-t-test. The resulting mean values AE SD, of three independent experiments, were reported in the histograms shown in Fig. 5B and C. As expected, we found that A2780/R treated cells displayed changes in these glycolytic enzymes similar to that observed in 2-DE gels. In particular, we found two immunoreactive GAPDH spots, corresponding to 2-DE spots 52 and 54, with a three and two-fold abundance increase, respectively, and another immunoreactive spot, the 2-DE spot 48, with a three-fold decrease. As regards ENO1, we detected two immunoreactive spots, spot 31 and spot 32, which showed a two-fold increased amount. 
Metabolic investigations
Proteomic and bioinformatic results suggested a possible cytotoxic effect of Aubipy c , directly or indirectly, on the glycolysis pathway. To strengthen these data, we evaluated the ability of Aubipy c -treated cells to consume glucose and to generate lactate. Glucose and lactate concentrations were measured in one millilitre of the medium supernatant harvested after 6, 12, 24, and 48 h the addition of 10 mM Aubipy c . Experiments were performed in triplicate. The resulting mean values AE SD were reported in the histograms in Fig. 6 . The glucose assay pointed out that up to 24 hours the glucose amount in the medium was similar in treated and untreated cells (Fig. 6A) . After 48 h, the glucose level was statistically higher in Aubipy c -treated cells ( p-value o 0.05 by two-tailed non-paired Student's-t-test). Indeed, in treated cells, we measured a glucose level about 2 times higher than in control cells suggesting an impairment in glucose utilization. Concerning lactate production, we found that after 6 h of treatment the lactate level was similar in treated and untreated cells (Fig. 6B) . The exposure of A2780/R cells to the gold compound elicited a clear decrease in their lactate secretion after 12 hours. The lactate amount was 1.5 times statistically lower in Aubipy c -treated cells ( p-value o 0.05). The lower lactate production in treated cells became more evident after 24 and 48 hours. Indeed, we assessed a lactate level of about two and four times lower, respectively, than in untreated cells. In order to investigate a possible functional relationship between these results and the decrease in LDHB abundance pointed out by 2D-MS analysis, we assessed the amount of this enzyme by western blot analysis. The western blot was performed in cells treated with 10 mM Aubipy c for 6, 12, 24, 48 h. Representative immunoblots were shown in Fig. 6C . For each time point, the optical density of a specific immunoreactive band was detected and its value was statistically analysed by two-tailed non-paired Student's-t-test. The resulting mean values AE SD, of three independent experiments, were reported in the histogram in Fig. 6C . We found, in Aubipy c -treated cells, a decrease in the LDHB amount after 12 h (about 1.8 fold), thus at the same time point in which the gold compound induced a decrease in lactate secretion. The LDHB decrease was more evident after 24 h (about 2 fold) and 48 h of treatment (about 3 fold).
Discussion
Aubipy c is a promising gold(III) compound which manifests an appreciable cytotoxicity toward the cell line A2780. Our previous proteomic study reporting the effects of Aubipy c on A2780 cisplatin-sensitive cells pointed out that gold treatment affected, directly or indirectly, several glycolytic enzymes. 31 In the present study, we extended the investigation to the cisplatin resistant subline A2780/R obtained from the parental cisplatin sensitive cell line A2780. We aimed to highlight the Aubipy c mechanism of action and to evaluate if this gold compound was able to affect proteins or biological processes/functions relevant for the acquisition of platinum-based drug resistance. Thus, we carried out a comparative proteomic study using 2-DE coupled with mass spectrometry. The results pointed out 57 differentially abundant proteins following Aubipy c treatment. Among them, 35 proteins resulted to be more abundant and 22 less abundant. These proteins play specific roles in a variety of biological processes. Most of them belong to three functional classes: metabolism, protein synthesis, and stress response and chaperones. In order to understand the biological meaning behind the list of 57 identified proteins, we processed them using the web-accessible program DAVID. This bioinformatics resource provides information about the GO terms enriched by a dataset of proteins or genes. The GO BP term protein folding resulted statistically enriched; it includes several members of the heat shock family, such as heat shock 70 kDa protein 4L, stress-70 protein mitochondrial and two forms of T-complex protein 1 subunit beta (CCT2). Heat shock proteins (HSPs) are over-expressed in a wide variety of human cancer cells 40 and some of them, such as Hsp27 and Hsp70, are involved in the prognosis of specific cancer types. 41 Furthermore, several studies reported an increase of HSP expression upon exposure to anticancer agents. These chaperones may participate in the stress response to drug-induced damage. 42 In line with these data, Aubipy c led to an increase of the amount of two forms of T-complex protein 1, subunit beta (CCT2). The TCP-1 chaperonin family known as 'eukaryotic cytosolic chaperonin containing TCP-1 (CCT) has a critical function in the folding of many proteins, including the cytoskeletal components actin and tubulin. 43 T-complex protein 1 subunits were already found to be involved in the process of chemoresistance by Castagna et al. 44 Conversely, the level of the other identified HSPs belongs to a subclass of FK506-binding proteins. 46 Several studies have proposed FKBP4 as a biomarker for tumorigenesis that provides chemoresistance through several different signaling pathways. 47 Based on the observed increased expression of these HSPs in cancer cells, their proposed role in metastasis and their anti-apoptotic properties, we hypothesized that Aubipy c treatment could induce cell death and overcome resistance to cisplatin, at least in part, through an impairment of protein folding machinery. We also observed an enrichment of GO BP terms involved in metabolism and energy production, such as the cellular metabolic process, the glucose metabolic process, and glycolysis. Most of the proteins involved in this enrichment are glycolytic enzymes, such as ENO1, GAPDH, ALDOC, and LDHB but also mitochondrial enzymes active in cellular respiration, such as dihydrolipoyl dehydrogenase (DLD) and ATP synthase subunit beta (ATP5B). In line with these data, the list of differentially abundant proteins also statistically enriched the GO pathway terms glycolysis and metabolism of carbohydrates. Worthy of note, some glycolytic enzymes involved in this functional analysis increased in abundance (ENO1 and two forms of GAPDH) while others (ALDOC, LDHB and a form of GAPDH) decreased after gold treatment. This trend was validated, regards to GAPDH and ENO1, by 2-D western blot analysis. Multiple forms of GAPDH were detected in cancer cell lines and normal tissue by twodimensional electrophoresis and western blot analysis. These forms, that differed by pI and M r , may play diverse roles in normal tissue and in cancer. 48 Genes of glucose metabolism have been reported to be ubiquitously over-expressed in cancer cells 49 and energy production is abnormally dependent on aerobic glycolysis. 50 The glycolytic shift in tumor cells compensates for mitochondrial dysfunction and provides resistance to apoptosis. Moreover, these metabolic alterations are responsible for chemoresistance in cancer therapy. Glyceraldehyde-3-phosphate dehydrogenase and alpha enolase seem to be relevant in the acquisition of drug resistance in cancer cell lines, due to their transcriptional regulation activity more than to their function in glycolysis. 51 It is noteworthy that some of these glycolytic enzymes pointed out by 2D-MS analysis, such as ENO1 and GAPDH, were also found to be affected by Aubipy c in the A2780/S cell line. 31 Others, such as ALDOC and LDHB, were identified only in this study on A2780/R. These differences could be related to biological processes/functions that are modulated in sensitive or resistant cell lines and relevant in the acquisition of drug resistance. Indeed, in previous studies, these two enzymes were found to be overexpressed in cisplatin-resistant A2780 cell line. 52, 53 In order to understand whether changes in abundance of these glycolytic enzymes could affect glycolysis we assessed glucose consumption and lactate production after gold treatment. The obtained results pointed out that Aubipy c lead to a lower lactate production followed by a reduction in glucose consumption. These findings were supported by the western blot against LDHB. We found a decrease of this enzyme after 12 h of Aubipy c treatment, thus at the same time point in which the gold compound produced a clear decrease in lactate secretion. It is known that LDHA kinetically favors the conversion of pyruvate to lactate in aerobic glycolysis and is therefore important for tumorigenesis. 54 LDHB could also mediate the same reaction, although it is more sensitive to substrate (pyruvate) inhibition and hence is thought to favour the conversion of lactate to pyruvate. 54 Despite this, the association of LDHB with cancer is complex. LDHB gene is silenced in several cancer types but is overexpressed or amplified in others, for example in human lung adenocarcinoma with KRAS mutation and in testicular germ cell tumors. 55 In addition, LDHB rather than LDHA appears to be necessary for triple-negative breast cancer. 56 Hence, the roles of LDHA and LDHB in aerobic glycolysis or in mitochondrial respiration of specific types of human cancers remain to be fully established. We can conclude that, at least as regards A2780/R cell line, there is a functional link between the decrease in lactate production and LDHB down-regulation. Hence, our functional proteomic analysis highlighted a potential negative effect of Aubipy c on glucose metabolism that causes a slowdown of glycolysis. This slowdown of the glycolytic pathway in A2780/R cells raised the question of whether glycolytic enzymes could be affected directly or indirectly by Aubipy c treatment. Go Ym et al. demonstrated, by proteomic analysis, that the gold(I) compound Auranofin (ARF) oxidized peptidylCys associated with proteins of glycolysis and gluconeogenesis in human colon carcinoma HT29 cells. 57 Moreover, to verify ARF-inhibition of glycolysis, they examined HT29 cells for pyruvate kinase (PK) enzyme activity and lactate amount. The result showed that both PK activity and lactate levels were significantly decreased by ARF treatment confirming the previous study on ARF-dependent inhibition of glycolysis in human neutrophils. 57 Given that ARF and Aubipy c are both Au-based drugs, we suppose that Aubipy c could also be able to oxidize the Cys residues of proteins involved in the glycolytic enzymatic pathways. Additional studies are needed to demonstrate this hypothesis.
Experimental
Materials RPMI 1640 cell culture medium, fetal calf serum (FCS), and phosphate-buffered saline were obtained from Celbio (Milan, Italy); sulforhodamine B (SRB) and cisplatin were obtained from Sigma (Milan, Italy). General chemicals were purchased from Sigma Aldrich (Italy), unless otherwise indicated.
Cell lines and culture conditions
The human ovarian carcinoma cell line resistant to cisplatin (A2780/R) was used for cytotoxicity and proteomic studies. Cells were maintained in RPMI1640 medium supplemented with 10% of FCS and antibiotics at 37 1C in a 5% CO 2 atmosphere and sub-cultured twice weekly.
Cell growth inhibition studies
The cytotoxic activity of Aubipy c was evaluated against the A2780/R cell line according to the method described by Skehan et al. 58 Aubipy c was diluted in DMSO as stock solution (10 mM).
Exponentially growing cells were seeded in 96-well microplates at a density of 5 Â 10 3 for 24 h prior to the addition of Aubipy c .
After 24 h, the medium was removed and replaced with fresh medium containing concentrations of Aubipy c ranging from 0.003 to 100 mM. Two different times of exposure to Aubipy c , 24 and 72 h, were used. For comparison purposes, the cytotoxicity of cisplatin was evaluated under the same experimental conditions. Then the cells were fixed with trichloroacetic acid and then stained with sulforhodamine B (SRB) solution, rinsed with 0.1% acetic acid and air-dried. At the end of the staining period, SRB was dissolved in 10 mM Tris-HCl solution (pH 10.5). Optical density was read in a microplate reader interfaced with the software Microplate Manager/PV version 4.0 (Bio-Rad Laboratories, Milan, Italy) at 540 nm. The IC 50 drug concentration resulting in a 50% reduction in the net protein content (as measured by SRB staining) in drug-treated cells as compared with untreated control cells was determined.
Trypan blue vital dye exclusion assay
A trypan blue vital dye exclusion assay was carried out to evaluate the viability of cells to be used in the proteomic studies. Briefly, we performed a time course at 24, 48 and 72 h drug exposures with 10 mM of Aubipy c (equal to 72 h-exposure IC50 value). Following exposures, 200 mL of trypsinized and re-suspended cells were mixed with 200 mL of 0.4% solution of trypan blue dye (Sigma-Aldrich) for 5 min. Numbers of total cells, live cells and dead cells, were immediately counted using a Neubauer micro-chamber (Brand GmbH, Wertheim, Germany) using a light microscope. All counts were done in duplicates of each sample. The reported data represent the mean of three independent experiments.
Two-dimensional gel electrophoresis
A2780/R cells were seeded in tissue-culture plates at 5 Â 
Image analysis and statistics
Three independent Aubipy c treatments were performed (biological replicates) and for each sample two 2-DE were carried out (technical replicates), so that in total 12 gels were analysed (6 gels for both A2780/R Aubipy c -treated and control cells). Colloidal Coomassie blue silver-stained gels were scanned using the Epson expression 1680 PRO scanner. The gel images were saved with a resolution of 300 dpi and in 16-bit TIFF format. Image analysis was carried out using the Progenesis SameSpots software v4.0 (Nonlinear Dynamics, UK), which allows spot detection, background subtraction and protein spot volume quantification. The gel image showing the highest number of spots and the best protein pattern was chosen as the reference image and its spots were then matched across all gels. This reference image was used to quantify and normalize the spot volumes. The spot volumes were normalized in each gel as relative volume (volume percentage), by dividing the raw quantity of each spot by the total quantity of all the spots included in the reference gel. Statistical analysis was performed using default parameters of the Progenesis SameSpots Stat module. The log 10 -normalized spot volume was used for the analysis as the log transformation improves normality. 61 The univariate data analysis was performed as one-way ANOVA on each spot individually. Then, a multivariate statistics was applied on all the ANOVA p-values by the False Discovery Rate (FDR) correction method. 34 Moreover, we performed a power analysis to assess the number of sample replicates that need to be analysed in order to confidently discover differentially abundant proteins. The accepted power threshold is Z0.8.
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We considered statistically differentially abundant spots having a corrected p-value (FDR) r0.05 and a power Z0.8. These spots were subjected to mass spectrometry analysis.
Mass spectrometry analysis
Electrophoretic spots were manually excised, destained, and acetonitrile dehydrated. A trypsin solution (0.25 mg mL À1 ) in 50 mM ammonium bicarbonate was added for in-gel protein digestion by overnight incubation at 37 1C. Solutions containing digested peptides were recovered and 20 mL of 1% TFA 50% ACN were added to each spot and sonicated for 10 minutes to maximize peptide recovery. At the end, for each spot all recovered peptide solutions were combined and concentrated. From each protein digest, 0.75 mL were spotted onto the MALDI target and allowed to air dry at room temperature. Then, 0.75 mL of matrix solution (saturated solution of a-cyano-4-hydroxycinnamic acid in 50% (v/v) acetonitrile and 0.5% (v/v) TFA) was applied to the sample and crystallized by air drying at room The applied laser wavelength and frequency were 353 nm and 100 Hz, respectively, and the percentage was set to 46%. Final mass spectra were produced by averaging 1500 laser shots targeting five different positions within the spot. Spectra were acquired automatically and the Flex Analysis software version 3.0 (Bruker) was used for their analysis and for the assignment of the peaks. The applied software generated a list of peaks up to 200, using a signal-to-noise ratio of 3 as the threshold for peak acceptance. Recorded spectra were calibrated using, as the internal standard, peptides arising from trypsin auto-proteolysis. The mass lists were filtered for contaminant removal: mass matrixrelated ions, trypsin auto-lysis and keratin peaks. Protein identification by Peptide Mass Fingerprint search was established using MASCOT search engine version 2.1 (Matrix Science, London, UK, http://www.matrixscience.com) through the UniProtKB database (http://www.uniprot.org/). Taxonomy was limited to Homo sapiens, a mass tolerance of 100 ppm was allowed, and the number of accepted missed cleavage sites was set to one. Alkylation of cysteine by carbamidomethylation was considered a fixed modification, while oxidation of methionine was considered as a possible modification. The criteria used to accept identifications included the extent of sequence coverage, the number of matched peptides, and a probabilistic score of p o 0.05. 
Bioinformatic functional analysis
LDHB western blot analysis
A2780/R cells were prepared as described in paragraph ''Glucose and Lactate assay''. Cells were harvested after 6, 12, 24, 48 h the addition of Aubipy c and lysed in RIPA buffer (50 mM Tris-HCl pH 7.0, 1% (v/v) NP-40, 150 mM NaCl, 2 mM ethylene glycol bis(2-aminoethyl ether)tetra-acetic acid, 100 mM NaF) containing a human protease inhibitor cocktail (Sigma). The cells were sonicated (15 s) and protein extracts were cleared by centrifugation at 8000g, 4 1C for 15 min. Protein samples (15 mg) were separated on 4-16% gradient SDS-PAGE precast gels (Bio-rad) and transferred onto a PVDF membrane (Bio-rad). The relative amount of the LDHB was assessed with an appropriate polyclonal antibody (AV48210 Sigma, Milan, Italy). According to datasheets, antibody was employed with a 1 : 1000 dilution in 2% milk. After incubation with horseradish peroxidase (HRP)-conjugated anti-mouse IgG (1 : 2000) (Amersham Biosciences), immune complexes were detected with the enhanced chemiluminescence (ECL) detection system (GE Healthcare). The PVDF membrane was exposed to autoradiographic films (Hyperfilm MP; Amersham Biosciences) for 1-30 minutes. For quantification, the blot was subjected to densitometric analysis using Quantity One Software (Bio-Rad). The intensity of the immunostained bands was normalized with the total protein intensities measured by Coomassie brilliant blue R-250 from the same blot. Statistical analysis, of three independent experiments, was performed by two-tailed non-paired Student's-t-test using Graphpad Prism 6. A p-value o 0.05 was considered statistically significant.
Conclusion
In summary, the data presented herein strongly correlate with the previous study on the human ovarian cancer cisplatinsensitive cell line (A2780/S). We demonstrated that Aubipy c induced in these two cell lines similar changes in abundance of proteins. Indeed, the gold compound affected proteins belong to the same functional categories (such as stress response and chaperones, protein synthesis, glucose metabolism). In particular, we found that Aubipy c affected glycolytic enzymes such as GAPDH and ENO1. However, our proteomic studies also pointed out some differences. In A2780/S we found a decrease in abundance of PKM and PGK1 while in A2780/R we observed a decrease of ALDOC and LDHB. These differences could be related to biological processes/ functions that are modulated in sensitive or resistant cell lines and relevant in the acquisition of drug resistance. The interesting finding of this proteomic study is that it has provided further evidence for the glycolytic implication for the cytotoxic effects of Aubipy c . Based on these data, we can state that a down-regulation of glucose metabolism might explain, at least in part, the biological effects of this gold compound. Yet, it is not possible to establish whether Aubipy c acts by directly inhibiting the identified glycolytic enzymes or if beyond the slowdown of glycolysis, other molecular mechanisms are operative.
Altogether, our two proteomic studies provide a solid starting point for further study on Aubipy c mechanism of action. An additional study is actually required to clarify the specific role played by the other identified proteins (such as HSPs) and their corresponding pathways in cell response to drug-induced damage. Moreover, analyses are needed to demonstrate if Aubipy c is able to bind directly these proteins or at least some of them.
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